MAP2K7 and fibrosarcoma: Accumulating evidence has demonstrated that the KRASG12D mutation predominantly causes the rapidly accelerated fibrosarcoma/mitogen–activated protein kinase/extracellular regulated protein kinase (RAF/MEK/ERK) signaling pathway to promote PDAC progression (25, 26).